iMDx reports Q3 2026 results, FDA review of GraftAssureDx paused on information requestNov 16Quarterly updateInsight Molecular Diagnostics Inc.
Insight Molecular Diagnostics files offering as FDA review of GraftAssureDx continuesNov 16FinancingInsight Molecular Diagnostics Inc.
Insight Molecular Diagnostics amends Chronix merger royalty terms againSep 21M&AInsight Molecular Diagnostics Inc.
iMDx says FDA sought more data on GraftAssureDx, gives itself 180 days to answerAug 10Quarterly updateInsight Molecular Diagnostics Inc.